Sin-Hee Park1, Eugenia Belcastro1, Hira Hasan1, Kensuke Matsushita2, Benjamin Marchandot2, Malak Abbas2, Florence Toti1, Cyril Auger1, Laurence Jesel1,2, Patrick Ohlmann2, Olivier Morel3,4, Valérie B Schini-Kerth5. 1. Regenerative Nanomedicine, Faculty of Pharmacy, UMR 1260, INSERM (French National Institute of Health and Medical Research), University of Strasbourg, 67000, Strasbourg, France. 2. Service de Cardiologie, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France. 3. Regenerative Nanomedicine, Faculty of Pharmacy, UMR 1260, INSERM (French National Institute of Health and Medical Research), University of Strasbourg, 67000, Strasbourg, France. olivier.morel@chru-strasbourg.fr. 4. Service de Cardiologie, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France. olivier.morel@chru-strasbourg.fr. 5. Regenerative Nanomedicine, Faculty of Pharmacy, UMR 1260, INSERM (French National Institute of Health and Medical Research), University of Strasbourg, 67000, Strasbourg, France. valerie.schini-kerth@unistra.fr.
Abstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) and blood-derived microparticles are major mediators of cardiovascular disease, their impact on SGLT1 and 2 expression and function in endothelial cells (ECs) and isolated arteries remains unclear. METHODS: ECs were isolated from porcine coronary arteries, and arterial segments from rats. The protein expression level was assessed by Western blot analysis and immunofluorescence staining, mRNA levels by RT-PCR, oxidative stress using dihydroethidium, nitric oxide using DAF-FM diacetate, senescence by senescence-associated beta-galactosidase activity, and platelet aggregation by aggregometer. Microparticles were collected from blood of patients with coronary artery disease (CAD-MPs). RESULTS: Ang II up-regulated SGLT1 and 2 protein levels in ECs, and caused a sustained extracellular glucose- and Na+-dependent pro-oxidant response that was inhibited by the NADPH oxidase inhibitor VAS-2780, the AT1R antagonist losartan, sotagliflozin (Sota, SGLT1 and SGLT2 inhibitor), and empagliflozin (Empa, SGLT2 inhibitor). Ang II increased senescence-associated beta-galactosidase activity and markers, VCAM-1, MCP-1, tissue factor, ACE, and AT1R, and down-regulated eNOS and NO formation, which were inhibited by Sota and Empa. Increased SGLT1 and SGLT2 protein levels were observed in the rat aortic arch, and Ang II- and eNOS inhibitor-treated thoracic aorta segments, and were associated with enhanced levels of oxidative stress and prevented by VAS-2780, losartan, Sota and Empa. CAD-MPs promoted increased levels of SGLT1, SGLT2 and VCAM-1, and decreased eNOS and NO formation in ECs, which were inhibited by VAS-2780, losartan, Sota and Empa. CONCLUSIONS: Ang II up-regulates SGLT1 and 2 protein expression in ECs and arterial segments to promote sustained oxidative stress, senescence and dysfunction. Such a sequence contributes to CAD-MPs-induced endothelial dysfunction. Since AT1R/NADPH oxidase/SGLT1 and 2 pathways promote endothelial dysfunction, inhibition of SGLT1 and/or 2 appears as an attractive strategy to enhance the protective endothelial function.
BACKGROUND:Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk in type 2 diabetespatients independently of glycemic control. Although angiotensin II (Ang II) and blood-derived microparticles are major mediators of cardiovascular disease, their impact on SGLT1 and 2 expression and function in endothelial cells (ECs) and isolated arteries remains unclear. METHODS: ECs were isolated from porcine coronary arteries, and arterial segments from rats. The protein expression level was assessed by Western blot analysis and immunofluorescence staining, mRNA levels by RT-PCR, oxidative stress using dihydroethidium, nitric oxide using DAF-FM diacetate, senescence by senescence-associated beta-galactosidase activity, and platelet aggregation by aggregometer. Microparticles were collected from blood of patients with coronary artery disease (CAD-MPs). RESULTS:Ang II up-regulated SGLT1 and 2 protein levels in ECs, and caused a sustained extracellular glucose- and Na+-dependent pro-oxidant response that was inhibited by the NADPH oxidase inhibitor VAS-2780, the AT1R antagonist losartan, sotagliflozin (Sota, SGLT1 and SGLT2 inhibitor), and empagliflozin (Empa, SGLT2 inhibitor). Ang II increased senescence-associated beta-galactosidase activity and markers, VCAM-1, MCP-1, tissue factor, ACE, and AT1R, and down-regulated eNOS and NO formation, which were inhibited by Sota and Empa. Increased SGLT1 and SGLT2 protein levels were observed in the rat aortic arch, and Ang II- and eNOS inhibitor-treated thoracic aorta segments, and were associated with enhanced levels of oxidative stress and prevented by VAS-2780, losartan, Sota and Empa. CAD-MPs promoted increased levels of SGLT1, SGLT2 and VCAM-1, and decreased eNOS and NO formation in ECs, which were inhibited by VAS-2780, losartan, Sota and Empa. CONCLUSIONS:Ang II up-regulates SGLT1 and 2 protein expression in ECs and arterial segments to promote sustained oxidative stress, senescence and dysfunction. Such a sequence contributes to CAD-MPs-induced endothelial dysfunction. Since AT1R/NADPH oxidase/SGLT1 and 2 pathways promote endothelial dysfunction, inhibition of SGLT1 and/or 2 appears as an attractive strategy to enhance the protective endothelial function.
Authors: Chintan N Koyani; Ioanna Plastira; Harald Sourij; Seth Hallström; Albrecht Schmidt; Peter P Rainer; Heiko Bugger; Saša Frank; Ernst Malle; Dirk von Lewinski Journal: Pharmacol Res Date: 2020-05-17 Impact factor: 7.658
Authors: Matthias Oelze; Swenja Kröller-Schön; Philipp Welschof; Thomas Jansen; Michael Hausding; Yuliya Mikhed; Paul Stamm; Michael Mader; Elena Zinßius; Saule Agdauletova; Anna Gottschlich; Sebastian Steven; Eberhard Schulz; Serge P Bottari; Eric Mayoux; Thomas Münzel; Andreas Daiber Journal: PLoS One Date: 2014-11-17 Impact factor: 3.240
Authors: Rongjun Zou; Wanting Shi; Junxiong Qiu; Na Zhou; Na Du; Hao Zhou; Xinxin Chen; Li Ma Journal: Cardiovasc Diabetol Date: 2022-06-15 Impact factor: 8.949
Authors: Camila I Irion; Monique Williams; Jose Condor Capcha; Trevor Eisenberg; Guerline Lambert; Lauro M Takeuchi; Grace Seo; Keyvan Yousefi; Rosemeire Kanashiro-Takeuchi; Keith A Webster; Karen C Young; Joshua M Hare; Lina A Shehadeh Journal: Int J Mol Sci Date: 2022-06-15 Impact factor: 6.208